Citations

Clear

2228 citation(s) found for "Le, Anne".

Longitudinal Detection of Circulating Tumor DNA in Children with Pleuropulmonary Blastoma: A Report from the International PPB/DICER1 Registry
Schultz, Kris Ann P , Field, Amanda L , Mallinger, Paige H R , Xu, Chenyu , Deonovic, Benjamin , Nelson, Alexander T , Watson, Dave , Hagedorn, Kelly , Olson, Damon R , Kamihara, Junne , Chen, Kenneth S , Mitchell, Sarah G , Wilson, David B , Amend, Christina E , Mize, William , Su, Yan , Duan, Chao , Yue, Zhixia , Gao, Chao , Klega, Kelly S. , Dehner, Louis P , Messinger, Yoav H , Crompton, Brian D , Harris, Anne K , Hill, Dana Ashley

Mayo Clinic

Clinical Cancer Research | November 17, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1158/1078-0432.ccr-26-1981 | PMID 43043066 Get It

Abstract Purpose: Pleuropulmonary blastoma (PPB) is the most common lung cancer of early childhood. Nearly all PPBs have biallelic DICER1 variants: a loss-of-function allele (often germline) and a second RNase IIIb domain "hotspot" substitution. Except in somatic mosaicism, these hotspots are tumor-specific and ideal liquid biopsy targets. Experimental Design: For individuals with PPB enrolled in the International PPB/DICER1 Registry, blood samples were collected at timepoints coordinated with clinical venous access. Tumor sequencing identified each patient's RNase IIIb hotspot, enabling personalized droplet digital PCR assays to detect that variant in circulating tumor DNA (ctDNA). Results: We analyzed 482 samples from 20 type I and 53 type II/III PPB patients. Among 13 pre-operative type II/III patients sampled pretreatment, 11 (85%) had detectable ctDNA, with tumor size moderately correlated with ctDNA burden (Spearman's ρ=0.574, p=0.051). In contrast, among 8 patients sampled after resection but before chemotherapy, none had detectable ctDNA (p<0.001 vs. unresected). After chemotherapy initiation, ctDNA levels spiked within 1–2 days before rapidly declining. During post-event surveillance, ctDNA was detectable a median of 5.3 weeks before clinical progression (21.7 weeks for negative samples; p=0.001). In type I PPB, DICER1 variants were detectable only in patients with somatic mosaicism. Conclusions: In type II/III PPB, ctDNA correlates with tumor size and resection status. The transient rise and fall in ctDNA following initiation of chemotherapy suggests that ctDNA could serve as a real-time in vivo assay of tumor responsiveness, and these findings support further investigation as a pharmacodynamic biomarker for disease response and recurrence detection.
Predictors of learning the memory support system in individuals with amnestic mild cognitive impairment
Koay, Jun Min , Grant, Jeremy G , Aghamoosa, Stephanie , Shandera-Ochsner, Anne L, Chandler, Melanie J

Mayo Clinic

Journal of Clinical and Experimental Neuropsychology | November 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-9

10.1080/13803395.2026.2762996 | PMID 43018120 Get It

Disagreement Between Outpatient Complications in the USNWR ENT Ratings and Clinical Adjudication
Pollock, Benjamin D , Anderson, Stephanie S., Vaver, Anne M, Devkaran, Subashnie, Tasche, Kendall K.

Mayo Clinic

Otolaryngology–Head and Neck Surgery | October 13, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/ohn.70494 | PMID 42867264 Get It

Abstract Objective In 2024, the US News and World Report (USNWR)'s Best Hospitals began reporting complications following elective outpatient otolaryngology procedures in its ears, nose, and throat (ENT) ranking. However, this methodology has not been clinically adjudicated in a peer‐reviewed domain. We aimed to conduct manual health record adjudication to assess whether the USNWR methodology accurately attributes complications following elective outpatient otolaryngology procedures. Study Design Case‐cohort. Setting A case‐cohort of n = 80 elective, outpatient otolaryngology procedure/complication pairings from January 2019 to October 2023 across four academic medical centers using the 2024 USNWR otolaryngology procedure subgroups and Solventum Ambulatory Potentially Preventable Complications (AM‐PPC) software. Methods We used the AM‐PPC‐defined complication types as our standard of comparison for our clinical adjudication. Using the electronic health record, we adjudicated: (1) Was there agreement (yes/no) on complication type between our clinical adjudication and the Solventum AM‐PPC software? (2) Was the complication clinically related to, or a sequela of, the index otolaryngology procedure (yes/no)? Results The clinical adjudication agreed on complication type in 59/80 (74%) of patients, and 63/80 (79%) were judged to be clinically related to the index otolaryngology procedure. In total, 50/80 (63%) complications were adjudicated to be in agreement on both the complication type and clinical relatedness to the index procedure, while 9/80 (11%) complications did not agree with the complication type nor were clinically related to the index procedure. Conclusion Outpatient complications reported in the USNWR ENT rating lack the specificity to exclude patients whose complications are sequelae of chronic underlying conditions or related to concurrent, non‐otolaryngology procedures.
The Baseline Molecular Profile of Late Relapse: Identifying Drivers of Delayed Recurrence in DLBCL
Masar, Michal , Walker, Janek S. , Vodicka, Prokop , Dropik, Abigail R , Xianyu, Zilin , Maurer, Matthew , Habermann, Thomas , Mou, Eric , Witzig, T.E. , Ansell, Stephen M , Klener, Pavel , Cerhan, James R , Trnĕný, Marek , Wang, Yucai , Novak, Anne J

Mayo Clinic

Hematological Oncology | October 12, 2026 | Volume: 44 | Issue: 6 | Pages: No page available

10.1002/hon.70275 | PMID 42861738 Get It

Top Ten Tips Palliative Care Clinicians Should Know About Caring for People Receiving Critical Care for Cardiovascular Disease
Song, Anne , Mehta, Ankita , Byrne-Martelli, Sarah E , Swol, Justyna , Godfrey, Sarah J, Robbins-Welty, Gregg A

Mayo Clinic

Journal of Palliative Medicine | October 8, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/10966218261496677 | PMID 42844232 Get It

Cardiovascular disease (CVD) remains the leading cause of death worldwide and is a major driver of critical illness, resulting in admission to cardiac intensive care units (CICUs). Patients with acute, life-threatening CVD often experience episodes of acute decompensation characterized by high symptom burden that may portend progressive loss of function, significantly impair quality of life (QOL), and involve high-intensity, technologically advanced therapies to sustain life. Despite these advances, up to 30% of patients die during CICU hospitalizations, and those who survive may subsequently face persistent functional impairment and psychosocial distress. During critical CVD (CCVD), patients often endure prognostic uncertainty and face complex decisions regarding life-sustaining therapies alongside refractory symptoms. Thus, care that focuses exclusively on disease-directed or life-prolonging therapies is often insufficient to address the full spectrum of patient and caregiver needs. When integrated alongside intensive cardiovascular care, palliative care (PC) offers a complementary and essential approach to the management of CCVD to inform therapeutic decisions, improve QOL, and address psychosocial and spiritual well-being. In this article, a multidisciplinary team featuring PC clinicians (physicians, nurse practitioners, social worker, psychologist, and chaplain), cardiologists, cardiac surgeons, cardiothoracic anesthesiologists, and intensivists present evidence-based guidance in a “Top Ten Tips” format to support PC clinicians caring for CICU patients and their caregivers.
Tirzepatide and the Incidence of Atrial Fibrillation in Adults With Overweight or Obesity: An Updated Meta‐Analysis of Randomized Controlled Trials
Mansouri, Ensieh S. , Queiroga, Flavia , Barbosa, Lucas , Azevedo, Anne K. , Donaldy, Webster , Mirbolouk, Mohammad Jafar, Blair, Camila V. , Rivera, André , Félix, Iuri Ferreira , Abreu, Marconi , Deshmukh, Abhishek , Barbosa, Lucas Mendes , Ferreira Felix, Iuri , Deshmukh, Abhishek J , DeSimone, Christopher V , Queiroga, Flavia Firmino de , Azevedo, A K , Mirbolouk, M J, DeSimone, Christopher V. , Rivera, A

Mayo Clinic

Journal of the American Heart Association | September 9, 2026 | Volume: 15 | Issue: 18 | Pages: No page available

10.1161/jaha.125.044249 | PMID 42714458 Get It

Background Tirzepatide is a dual agonist for glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptors, with proven efficacy in weight loss and improvement in cardiovascular outcomes. However, the effects of tirzepatide on the incidence of atrial fibrillation in patients with overweight or obesity remain unclear. Methods PubMed, Embase, and Cochrane Library were searched for randomized controlled trials comparing tirzepatide versus placebo for individuals with overweight or obesity. Odds ratios (ORs) with 95% credible intervals (CrIs) were pooled using a Bayesian binomial‐normal hierarchical model, appropriate for rare‐event outcomes. Results Our meta‐analysis included 10 randomized controlled trials, including 6515 individuals, of whom 4491 (68.9%) were randomized to tirzepatide. The pooled OR was 2.20 (95% CrI, 0.81–6.75) for atrial fibrillation, 2.16 (95% CrI, 0.90–5.87) for atrial arrhythmia, and 1.84 (95% CrI, 1.04–3.90) for any arrhythmia. Conclusions Tirzepatide was not associated with atrial fibrillation or atrial arrhythmia. Although higher odds of overall arrhythmias were observed, event rates were low and the findings should be interpreted cautiously.
Pearls & Oy-sters: DPPX Antibody-Associated Encephalitis in a Patient With Diarrhea, Tremor, Ocular Flutter, and Cognitive-Psychiatric Changes
Sosa, Santiago Martinez , Webb, Lauren M. , Thomsen, Anna, Rigler, Nicole, Coon, Elizabeth A. , Toledano, Michel , McKeon, Andrew , Banks, Samantha A. , Martinez Sosa, Santiago , Paz Soldán, M Mateo , Coon, Elizabeth Anne , Toledano, Michel , McKeon, Andrew , Syc-Mazurek, Stephanie B , Banks, Samantha , Soldán, M. Mateo Paz , Syc‐Mazurek, Stephanie B.

Mayo Clinic

Neurology | September 1, 2026 | Volume: 107 | Issue: 7 | Pages: No page available

10.1212/wnl.0000000000218522 | PMID 42679339 Get It

Development and Temporal Validation of AI ‐Enhanced Human Epithelial Type 2 Indirect Immunofluorescence Image Analysis for Specific Autoantibody Prediction in Systemic Autoimmune Rheumatic Diseases
Vanderboom, Patrick, Dasari, Surendra, Sandino-Bermúdez, Marlon J , Tebo, Anne E. , Snyder, Melissa, Duarte‐García, Alí

Mayo Clinic

Arthritis & Rheumatology | August 28, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/art.70312 | PMID 42663162 Get It

Objective Antinuclear antibody (ANA) indirect immunofluorescence (IIF) is the reference standard but depends on subjective pattern interpretation. We tested whether artificial intelligence (AI) applied to ANA IIF images could identify specific autoantibodies. Methods We assembled a cohort of ANA‐positive patients (human epithelial type 2 IIF titer ≥1:80) with anti–double‐stranded DNA (dsDNA), anti‐Smith (Sm) antibody, ribonucleoprotein (RNP), anti‐Sjögren's disease‐related antigen A (SSA), anti‐Sjögren's disease‐related antigen B (SSB), anti‐topoisomerase I (Scl‐70), or centromere antibody (CMA) testing within 90 days. The development cohort (December 12, 2016–December 31, 2022) included the first ANA test per patient. Two AI architectures were trained for each autoantibody. Performance was assessed using area under the receiver operating characteristic curve (AUROC), sensitivity, specificity, and accuracy; comparisons with IIF patterns were summarized as pattern‐antibody agreement. A prospective cohort (January 1, 2023–August 20, 2024), including a dsDNA assay transition, provided temporal validation. Results Among 512,959 patients, 47,890 met inclusion criteria (mean age 55 [SD 17.6], 78% female). Models for CMA, dsDNA, Sm, SSA, and SSB achieved AUROC ≥0.80 (CMA highest: AUROC 0.95, accuracy 94.2%, specificity 95.3%). Compared with associated IIF patterns, dsDNA and Sm models more often classified antibody‐negative cases as negative (dsDNA 88.2% vs 54.7%; Sm 82.6% vs 60.3%) while similarly classifying antibody‐positive cases. Performance for RNP (AUROC 0.68) and Scl‐70 (AUROC 0.59) was lower. In the prospective cohort (n = 21,427), performance was similar; dsDNA discrimination remained stable across assays (AUROC ~0.85). Conclusion AI applied to ANA IIF images identified specific autoantibodies and often improved classification of antibody‐negative cases versus simplified pattern‐based comparators. These findings support its potential to standardize ANA interpretation and triage or reduce confirmatory testing. image
Epidemiologic Study of Transfusion-Related Alpha-Gal Syndrome
Kaufman, Richard M., Hoen, Anne G., Khan, Jenna, Knudson, C. Michael, Romero, Andres E. Mindiola, Mo, Allison , Takanashi, Minoko , Collaborative, UPTICK Study Group; for the Biomedical Excellence for Safer Transfusion (BEST), Cardigan, Rebecca, Stanworth, Simon J., Commins, Scott P. , Scherer, Emily A., Davenport, Robertson D., Afraz, Sajjad, Andrews, Jennifer , Casey, John, Sullivan, Jensyn Cone , Cousins, Clara C. , Giorgi, Valeria De , Delaney, Meghan, DelBaugh, Regina M. , Gilstad, Colleen W. , Gofton, Alexander , Hill, Kate, Hogan, Keenan , Humbrecht, Catherine , Ikeda, Kazuhiko, Javanbakht, Ayda, Juskewitch, Justin E, Wojtowicz, Monique M. Menzies, Miller, Maureen J., Mills, Georgia, Nelson, Anna C. , Pauly, Marie C., Poisson, Jessica , Raval, Jay S., Samy, Nikitha, Sato, Tomohiko, Takeda, Yoshinori , Thibodeaux, Suzanne R. , Nunen, Sheryl van, Virk, Mrigender S., West-Mitchell, Kamille, Yamanouchi, Jun, Yoshihara, Satoshi, Zheng, X. Long, Ziman, Alyssa, Cone Sullivan, Jensyn , Kaufman, Richard Max , Hoen, Anne Gatewood , Knudson, Charles Michael , Metcalf, Ryan A. , Schäfer, Richard , Dunbar, Nancy M. , Cardigan, Rebecca A. , Stanworth, Simon J., Scherer, Emily A. , Cervinski, Mark A , Arai, Yasuyuki , Brugnara, Carlo , Allen, Elizabeth S. , Aurich, Konstanze , Casey, John , Cohn, Claudia S. , Crowe, Elizabeth P , Delaney, Meghan , Hendrickson, Jeanne E. , Hill, Kate, Ikeda, Kazuhiko , Jacquot, Cyril , Javanbakht, Ayda , Juskewitch, Justin E. , Lu, Wen , Wojtowicz, Monique Menzies , Miller, Maureen J. , Nelson, Anna , Pagano, Monica B. , Pauly, Marie-Christin , Saifee, Nabiha H , Sato, Tomohiko, Takeda, Yoshinori, Tiberghien, Pierre , Nunen, Sheryl van, Virk, Mrigender , Wood, Erica M , Yoshihara, Satoshi , Zheng, X. Long, Ziman, Alyssa

Mayo Clinic

JAMA Internal Medicine | August 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jamainternmed.2026.3983 | PMID 42636004 Get It

Importance Recent case reports suggest that B antigen–containing blood products may be associated with anaphylactic transfusion reactions in recipients with preformed immunoglobulin E to galactose- α -1,3-galactose (alpha-gal). Objective To test the association of local alpha-gal syndrome (AGS) prevalence and allergic transfusion reaction (ATR) in patients with blood type O. Design, Setting, and Participants In this international, multicenter, retrospective cohort study at academic medical centers, sites were assigned to AGS high- or low-prevalence clusters based on the known geographic distribution of AGS. Data were collected on platelet or plasma transfusions and ATRs during 2020 to 2024. Consecutive patients receiving platelet or plasma transfusions were included. Exposures Patients with blood type O who received B or AB units and patients with blood type O who received O units (reference group) in AGS high- and low-prevalence clusters were compared. Main Outcomes and Measures Before data collection, the hypothesis was that if transfusion-related alpha-gal syndrome (TRAGS) is a true clinical entity, excess ATRs to group B or AB units would be detected in AGS high-prevalence regions exclusively. The main measure was the overall risk ratio (RR) for ATRs to B or AB plasma or platelets in AGS high- vs low-prevalence clusters. Results In total, 558 823 platelet and plasma transfusions at 40 sites in 5 countries were analyzed, of which ATRs occurred in 1744 transfusions (0.3%). In the US AGS high-prevalence cluster (9 sites), significantly more ATRs of any severity occurred among patients with blood type O who received B or AB units vs patients with blood type O who received O units (overall RR, 3.93; 95% CI, 2.96-5.21; P < .001). In contrast, in the primary analysis of the AGS low-prevalence cluster (15 sites), excess ATRs to B or AB units were not detected. In subgroup analyses among patients with blood type O receiving B units, the RR for moderate to severe ATRs was 9.14 (95% CI, 5.39-15.52; P < .001) in the AGS high-prevalence cluster vs 2.15 (95% CI, 1.34-3.47; P = .002) in the AGS low-prevalence cluster. Outside the US, a signal consistent with TRAGS was not detected. Conclusions and Relevance This cohort study provides provocative epidemiologic evidence that TRAGS may be a unique manifestation of AGS and a previously unrecognized risk associated with transfusion. In AGS high-prevalence regions, blood collectors and hospital transfusion services should consider approaches to preventing severe ATRs from B or AB plasma or platelet units.
Perinatal and Early-Life Exposures and Risk of Non-Hodgkin Lymphoma
Cholack, George , Kleinstern, Geffen , Robinson, Dennis P. , Thompson, Carrie A. , Call, Timothy G. , Feldman, Andrew L. , Larson, Melissa C. , Mwangi, Raphael , Ansell, Stephen M. , Novak, Anne J. , Kay, Neil E. , Slager, Susan L. , Cerhan, James R. , Cholack, George A , Habermann, Thomas , Cozen, Wendy , Slager, Susan L , Cerhan, James R , Feldman, Andrew L , Kay, Neil E , Ansell, Stephen M , Novak, Anne J , Call, Timothy G , Larson, Melissa C , Habermann, Thomas M. , Cozen, Wendy

Mayo Clinic

Cancers | August 18, 2026 | Volume: 18 | Issue: 16 | Pages: 2666

10.3390/cancers18162666 | PMID 42649977 Get It

Background: Perinatal and early-life factors may influence non-Hodgkin lymphoma (NHL) risk, but study results have been mixed and exposure data for childhood ages are limited. Herein, we investigated associations of these exposures with risk of NHL and common subtypes. Methods: This case–control study included 2280 NHL cases and 2253 controls, enrolled from 2002 to 2014 at the Mayo Clinic Rochester. Self-reported perinatal and early-life exposures included maternal age at birth, birth order, birthweight, time breastfed, height and weight at ages 7, 12, and 18 years relative to peers, and age and weight when growth ceased. We used logistic regression to estimate odds ratios (ORs) and 95% confidence intervals (CIs), adjusting for design variables and potential confounders. Linear trend tests were performed for ordinal variables, and heterogeneity tests were performed to evaluate whether associations varied across four NHL subtypes. Results: After multivariable adjustment, greater birth weight (OR = 1.15 for quartile 4 vs. 1; p-trend = 0.04), weight at age 7 relative to peers (compared to average, OR = 1.05 for heavy and OR = 0.87 for thin; p-trend = 0.002), and weight when growth ceased (OR = 1.30 for quartile 4 vs. 1; p-trend < 0.001) were associated with increased NHL risk. An inverse association was observed for breastfeeding duration with NHL risk (OR = 0.77 for >6 months vs. never; 95% CI 0.61–0.97). Associations did not significantly vary by major NHL subtype (p-heterogeneity > 0.05). Other perinatal and early-life exposures were not associated with NHL risk. Conclusions: Greater body weight at birth and through childhood may be associated with increased NHL risk, potentially extending the life-course perspective on adiposity and lymphomagenesis, with implications for prevention.